SCHEMBL5771936

SCHEMBL5771936

Fc1ccc(-c2ncn(C3CCNC3)c2-c2ccc3nnc(-c4ccccc4)n3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.52
MAPK13 O15264 3/20 0.52
MAPK12 P53778 3/20 0.52
MAPK11 Q15759 3/20 0.52
TGFBR1 P36897 7/20 0.49
TGFBR2 P37173 1/20 0.46
RIPK2 O43353 1/20 0.45
DYRK3 O43781 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
PRKCG P05129 1/20 0.45
LCK P06239 1/20 0.45
LYN P07948 1/20 0.45
RET P07949 1/20 0.45
PIM1 P11309 1/20 0.45
PRKACA P17612 1/20 0.45
MAPK1 P28482 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
MAPK9 P45984 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5777214 0.83 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL5773544 0.75 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL5769493 0.75 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL5796403 0.72 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11PIM1
SCHEMBL6182792 0.72 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11RIPK2
SCHEMBL6183813 0.72 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11RIPK2
SCHEMBL6183811 0.72 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11RIPK2
SCHEMBL1639238 0.70 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11RIPK2
Vk-19911 SCHEMBL140202 0.69 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11RIPK2
SCHEMBL1906575 0.69 MAPK14 (0.88) MAPK14MAPK13MAPK12MAPK11RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370559-B1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS PFIZER PROD INC (US) 2006-04-19 EP disclosed
US-6696464-B2 POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK PFIZER INC 2004-02-24 US disclosed
EP-1370559-A1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS Pfizer Products Inc. (US) 2003-12-17 EP disclosed
US-20030096838-A1 Novel triazolo-pyridines anti-inflammatory compounds PFIZER INC. 2003-05-22 US disclosed
WO-2002072579-A1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS PFIZER PRODUCTS INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096838-A1 Novel triazolo-pyridines anti-inflammatory compounds MAPK1, CNKSR1, JAK1 MAPK14 15/4885MAPK13 60/4885MAPK12 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.